

# ChinaAMC China Focus Fund

Fund Factsheet | As of 30 May 2025

New Capital Investment Entrant Scheme (New CIES) Eligible fund



Investment involves risks, including the loss of principal. The price of units or shares of the Funds may go up as well as down. Past performance is not indicative of future results. The value of the Funds can be extremely volatile and could go down substantially within a short period of time. You should read the Fund's Placing Memorandum or Explanatory Memorandum and Product Key Facts Statement for details, including risk factors. Investors should not base investment decisions on this marketing material alone. Please note:

- The Fund seeks to take investment exposure to companies in or have significant business exposure to China. Investment in China-related companies and in Chinese markets may involve (i) heightened political, tax, economic, foreign exchange, liquidity and regulatory (including the QFI policy) risks, compared to more developed economies or markets; and (ii) concentration risk which may result in greater volatility than broad-based investments. The China A Share market is also unstable, subject to risks of stock suspension, government intervention and foreign investment restrictions.
- The Fund will obtain exposure to the A Share market, partly or fully by investing into access products and will be exposed to the counterparty risk of the issuer of the access products. The availability of access products is limited by applicable regulations in China, and as a result the cost of investment is subject to market supply and demand forces. Where the supply is low relative to the demand, acquiring access products may involve a higher cost or a premium.
- The Fund is subject to risks associated with the Stock Connect, such as change of relevant rules and regulations, quota limitations, suspension of the Stock Connect and information technology limitation. In the event that the Fund's ability to invest in A Shares through the Stock Connect on a timely basis is adversely affected, the Manager will rely on A Share access products investment.
- The Fund may invest in A Share ETFs and spot bitcoin/ether ETFs, thus is subject to the fees and charges and the risk of tracking errors of the relevant ETFs. If the Fund invests in synthetic ETFs, it will also subject to risks related to derivative instruments.
- There are risks and uncertainties associated with the current PRC tax laws, regulations and practices in respect of capital gains (which may have retrospective effect). Possible changes on the actual applicable tax rates imposed by the SAT and possible expiration of the current exemption of corporate income tax on capital gains may increase the Fund's tax liability and adversely affect the Fund's NAV.
- The Fund will hold investments denominated in currencies different to the base currency of the Fund, meaning the Fund will be at risk to adverse movements in the foreign currency rates.

## Investment Objective

The Fund seeks to provide investors with long term capital growth through exposure to China-related companies by investing in equities and equity related instruments.

## Fund Information<sup>1</sup>

Legal Structure	Hong Kong domiciled umbrella structure unit trust
Investment Manager	China Asset Management (Hong Kong) Limited
Trustee	Cititrust Limited
Custodian	Citibank, N.A. (Hong Kong branch)
Base Currency	USD
Fund Size	USD 22.10 million
Available Dealing Currencies	USD, EUR, GBP, AUD, SGD, HKD
Dealing Frequency	Daily
Performance Fee	10% of appreciation in the NAV per unit during a performance period above the high watermark of the relevant class of units


## Available Share Classes

Share Class	Launch Date	NAV per share	Bloomberg Code	ISIN Code
Class AUD	2010-12-10	AUD 19.859	CACFAUD HK	HK0000352911
Class EUR	2010-12-10	EUR 16.516	CACFEUR HK	HK0000352929
Class HKD	2010-12-10	HKD 14.329	CACFHKD HK	HK0000352945
Class SGD	2010-12-10	SGD 14.052	CACFSGD HK	HK0000352952
Class USD	2010-12-10	USD 13.907	CACFUSD HK	HK0000352960

Source: Data as of 30 May 2025, Bloomberg, unless specified otherwise.

Share Class	Subscription Fee	Investment Management Fee	Min Initial Subscription
Class AUD	Up to 5%	1.8% p.a.	AUD 1,000
Class EUR	Up to 5%	1.8% p.a.	EUR 1,000
Class HKD	Up to 5%	1.8% p.a.	HKD 1,000
Class SGD	Up to 5%	1.8% p.a.	SGD 1,000
Class USD	Up to 5%	1.8% p.a.	USD 1,000

## Fund Performance<sup>2</sup>



## Cumulative Performance (%)<sup>2</sup>

	1 Month	3 Month	6 Month	1 Year	Since Inception <sup>3</sup>	Annualized Since Inception <sup>3</sup>
Class AUD	3.63	-4.77	9.26	25.26	98.59	4.85
Class EUR	4.47	-10.23	0.47	15.97	65.16	3.53
Class HKD	5.50	-1.19	8.79	21.52	43.29	2.52
Class SGD	3.04	-6.31	3.84	15.66	40.52	2.38
Class USD	4.33	-2.02	7.96	21.24	39.07	2.30

## Yearly Performance (%)<sup>2</sup>

	2020	2021	2022	2023	2024	2025 YTD
Class AUD	16.27	1.17	-23.56	1.67	25.87	3.29
Class EUR	17.46	2.38	-24.04	-1.16	21.83	-2.02
Class HKD	27.23	-4.58	-28.64	2.36	13.61	8.41
Class SGD	25.75	-2.71	-29.08	0.62	18.11	1.51
Class USD	27.63	-6.11	-28.72	2.31	14.21	7.38

1 Please refer to the Explanatory Memorandum for full product disclosure including fees.

2 Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is calculated on NAV-to-NAV, with dividend reinvested. Since 28 July 2017, the Manager of the Fund changed from Citigroup First Investment Management Limited to China Asset Management (Hong Kong) Limited and the Trustee of the Fund changed from Cititrust (Cayman) Limited to Cititrust Limited. With effect from 11 November 2024, the investment strategy has been changed to allow investment in spot bitcoin ETFs and/or spot ether ETFs listed on the Stock Exchange of Hong Kong Limited or any other stock exchanges (such as the NASDAQ Stock Market in the United States). The performance prior to 2024 was achieved under circumstances that no longer apply.

3 Calculated since the inception date of respective share class.

Source: China Asset Management (Hong Kong) Limited and Bloomberg unless specified otherwise.

▲ Manager's Comment

In May, the Hong Kong market saw the Hang Seng Index rise by 5.29%, and the Hang Seng Tech Index increase by 1.63%. The fund recorded a positive return of 4.33%, slightly underperforming the Hang Seng Index by approximately 0.96%, but outperforming the MSCI China Index by about 1.6%.

In May, China gradually released several key economic indicators. In April, the value-added of industrial enterprises above designated size increased by 6.1% year-on-year. Fields related to new productive forces, such as industrial robots and new energy vehicles, expanded rapidly. However, the manufacturing PMI fell to 49, entering contraction territory, reflecting pressure from external demand. In the consumption sector, a mild recovery was observed, with total retail sales of consumer goods increasing by 5.1% year-on-year. Jewelry rose by 25%, and automobiles by 0.7%, while real estate-related consumption remained weak.

In terms of prices, the CPI fell slightly by 0.1% year-on-year, and the PPI decline widened to 2.7%, indicating continued deflationary pressure. Investment showed clear divergence: from January to April, urban fixed asset investment growth slowed to 4%. Investment in high-tech industries was strong, but real estate development investment fell by 10.3% year-on-year. Infrastructure and manufacturing became the main supports.

Financial data showed some improvement. In April, total social financing increased by 1.16 trillion yuan, and M2 growth rebounded to 8%. However, the M2-M1 gap widened to 6.5%, reflecting insufficient willingness of enterprises to activate funds. On the policy front, efforts continued: the central bank's reserve requirement cut released about 2.5 trillion yuan in liquidity. From January to April, industrial enterprise profit growth improved to 1.4%, confirming the initial effectiveness of counter-cyclical adjustments.

In May, China-US relations centered around tariff negotiations. Economically, the U.S. Q1 GDP preliminary annualized figure shrank by 0.3%, marking the first negative growth since 2022. April retail sales rose by 0.1% month-on-month, and the consumer confidence index fell to its lowest level since May 2020, indicating that tariffs have pushed up prices and suppressed consumption.

Inflation data showed mixed signals: U.S. April CPI rose by 2.3% year-on-year, a three-year low, but core PCE rose to 3.5%. PPI unexpectedly fell by 0.5% month-on-month, suggesting that companies are absorbing tariff costs, leading to declining profit margins.

Tariff negotiations made positive progress: within 90 days, the U.S. reduced the tariff increase on China to 30%, and China canceled or suspended corresponding retaliatory tariffs. Both sides established effective communication mechanisms, significantly improving market risk appetite. At the end of May, a U.S. court ruled that the Trump administration had "overstepped" in imposing comprehensive tariffs, further easing tariff concerns. However, the final outcome still depends on the Supreme Court's ruling, which remains uncertain.


The Federal Reserve faced a dilemma: it kept interest rates unchanged and warned of "exceptionally high economic uncertainty." Trump pressured for rate cuts, but Fed Chair Powell refused, highlighting the conflict between monetary policy and trade policy.

In May, Hong Kong stocks rose amid positive developments in China-U.S. tariff negotiations. The Hang Seng Index rose by 5.29% for the month. The healthcare sector led with a 10.10% gain, driven by accelerated overseas licensing of innovative drugs and valuation recovery, attracting continued capital inflows. The Hang Seng Tech Index rose by 1.63%, and the real estate sector increased by 1.8%, underperforming the Hang Seng Index.


Macroeconomic factors became key market variables. On May 12, the China-U.S. agreement led to a 2.98% single-day surge in the Hang Seng Index. However, the Fed's delayed rate cut and renewed tariff threats triggered market pullbacks. In the short term, the market is focused on tariff developments and domestic policy direction, with structural opportunities seen in innovative pharmaceuticals and new-quality consumption.

▲ Portfolio Allocation

Sector Exposure (%)



Geographical Exposure (%)



Source: China Asset Management (Hong Kong) Limited and Bloomberg unless specified otherwise. Data As of 30 May 2025.

Customer Hotline: (852) 3406 8686

Website: [www.chinaamc.com.hk](http://www.chinaamc.com.hk)

Email: [hkfund\\_services@chinaamc.com](mailto:hkfund_services@chinaamc.com)

Important Note

Investment involves risks. The price of the Fund's units may go up as well as down. Past performance is not indicative of future performance, future return is not guaranteed and a loss of your original capital may occur. This material does not constitute an offer or solicitation of any transaction in any securities or collective investment schemes, nor does it constitute any investment advice. This document is provided for information purposes only and shall not be relied upon for making any investment decision. Certain information or data in this document has been obtained from unaffiliated third parties; we have reasonable belief that such information or data is accurate, complete and up to the date as indicated; China Asset Management (Hong Kong) Limited accepts responsibility for accurately reproducing such data and information but makes no warranty or representation as to the completeness and accuracy of data and information sourced from such unaffiliated third parties. You should read the Fund's offering documents for further details, including risk factors. If necessary, you should seek independent professional advice. This material has been prepared and issued by China Asset Management (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission.